ArticleTurkish journal of medical sciences2026
Serum phosphoproteome alterations associated with cardiac troponin I levels in acute myocardial infarction.
Article in Turkish journal of medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/aim: Acute myocardial infarction (AMI) triggers systemic biochemical responses, including dynamic changes in the phosphorylation status of circulating proteins. However, the phosphoproteomic profile of serum in the context of AMI remains insufficiently characterized. This study aimed to investigate serum phosphoproteomic alterations associated with AMI and to explore potential correlations with markers of cardiac injury. Materials and methods: A comparative phosphoproteomic analysis was performed on serum samples obtained from eight patients with AMI and pooled healthy control samples. High-abundance serum proteins were depleted, and phosphopeptides were enriched using TiO Results: A total of 46 phosphoproteins were confidently identified, revealing distinct phosphorylation profiles between AMI and control samples. Increased phosphorylation levels were observed for solute carrier family 12 member 5, apolipoprotein L1, the low-molecular-weight isoform of kininogen-1, and osteopontin in AMI serum. Conversely, phosphorylated inter-alpha-trypsin inhibitor heavy chain H2, antithrombin III, histidine-rich glycoprotein, peroxiredoxin-4, GTPase ERas, and the 26S proteasome non-ATPase regulatory subunit 1 were reduced or undetectable. A strong negative correlation was found between apolipoprotein L1 phosphorylation and cardiac troponin I concentrations (r = -0.91; p = 0.0016). Conclusion: These findings demonstrate that serum phosphoproteomics can provide valuable insights into the molecular events associated with AMI. The inverse relationship between apolipoprotein L1 phosphorylation and cardiac troponin I levels suggests that phosphoproteomic profiling may aid in understanding myocardial injury mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.